- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04395170
Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.
A Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
The study population will be patients (≥18 years) hospitalized by COVID-19 but still with an early form of the disease (in states 1-3 of the ordinal scale) who do not require mechanical ventilation (invasive or non-invasive) and who can give their consent informed.
All the participants will receive non-specific supportive treatment for COVID-19 such as oxygen, IV liquid or corticosteroids. Additionally, they will be randomized to one of the following arms:
Experimental arm 1: Plasma with inactivation/reduction of pathogens from convalescent patients with COVID-19 and who at the same time receive support therapy, in the 200 - 250 mL scheme, on days 1 and 3 of the intervention.
Experimental arm: Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenous at a dose of immunoglobulin 10% IgG solution (10% mL vial) for:
Patient of 50 Kg or more, a dose of 50 mL will be applied on days 1 and 3 of treatment.
Patients of less than 50 Kg, the dose will be 1 mL / Kg, will be applied on days 1 and 3 of treatment.
This arm will be included once available. The supply of anti-COVID-19 human immunoglobulin produced by LifeFactors will be carried out once the national regulatory agency (Invima) grants authorization and/or the regulatory requirements for the production of medications are met.
Control arm: Standard (specific) therapy for COVID-19 according to the suggested pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are determined by the Colombian Health Regulatory Authorities.
Opintotyyppi
Ilmoittautuminen (Odotettu)
Vaihe
- Vaihe 2
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Santiago Jaramillo
- Puhelinnumero: +573128092776
- Sähköposti: sjaramillo@lifefactors.co
Opiskelupaikat
-
-
Antioquia
-
Medellín, Antioquia, Kolumbia
- LifeFactors Zona Franca SAS
-
Ottaa yhteyttä:
- Santiago Jaramillo
- Puhelinnumero: +57 3128092776
- Sähköposti: sjaramillo@lifefactors.co
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Obtaining the informed written consent before carrying out the study procedures, by the patients.
- Adult patients ≥18 years at the time of recruitment for the study.
- Patients with laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction on nasal/oropharyngeal swabs or any other relevant specimen <72 hours before randomization.
Patients requiring hospitalization for COVID-19 without mechanical ventilation (invasive or non-invasive, including an oxygen mask with reserve bag) and at least one of the following:
- Radiographic evidence of pulmonary infiltrates by images (chest radiography, computed tomography, etc.),
- Clinical evaluation (evidence of rales/crackles on examination) and oxygen saturation ≤ 94% in ambient air requiring supplemental oxygen.
- Patient with no more than 72 hours (3 days) of hospitalization prior to the administration of PC treatment (except the days after initial hospital admission for other reasons and prior to COVID-19 infection).
- Patients who do not have more than 10 days between the onset of symptoms (fever or cough) and the day of administration of treatment or the demonstration of the absence of anti-SARS-CoV-2 antibodies (patients with more than 10 days of symptoms they can only be included if a negative antibody result has been confirmed).
Exclusion Criteria:
- Patient in a state of pregnancy.
- Require mechanical ventilation (invasive or non-invasive, including oxygen mask with reserve bag) on examination.
- Participation in any other clinical trial of an experimental treatment for COVID-19.
- At the discretion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, regardless of the provision of treatments.
- Any incompatibility or allergy to the administration of plasma of human origin.
- Severe chronic kidney disease in stage 4 or requiring dialysis (that is, glomerular filtration rate <30).
- Any condition that in the investigator's opinion limits participation in the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Convalescent plasma
Plasma from patients recovering from COVID-19.
|
Plasma from convalescent patients with COVID-19 and at the same time receiving supportive therapy, with inactivation / reduction of pathogens, in the scheme of two doses of 200 - 250 mL administered on days 1 and 3 of the intervention.
|
Kokeellinen: Anti-COVID-19 human immunoglobulin
Anti-COVID-19 human immunoglobulin to be administered intravenously.
|
Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenously at a dose of immunoglobulin 10% IgG solution (10% mL vial) for: Patient of 50 Kg or more, a dose of 50 mL, administered on days 1 and 3 of treatment. Patient under 50 Kg, the dose will be 1 mL / Kg, administered on days 1 and 3 of treatment. The supply of anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S included once it has been authorized by INVIMA and/or the regulatory requirements in force for the production of drugs are met. |
Active Comparator: Standard (specific) therapy
Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities. To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin. |
Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities. To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Admission to ICU and/or mechanical ventilation
Aikaikkuna: One year
|
Admission to the intensive care unit with the requirement of mechanical ventilation (invasive or non-invasive) due to Acute Respiratory Distress Syndrome by COVID-19.
|
One year
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Length of hospital stay
Aikaikkuna: One year
|
Time in the hospital from admission to discharge or death.
|
One year
|
Neutralizing antibody (IgG) titers against COVID-19
Aikaikkuna: One year
|
Neutralizing antibody (IgG) titers against COVID-19
|
One year
|
Safety - Adverse events
Aikaikkuna: One year
|
Non-serious adverse events (NSAEs) and serious adverse events (SAEs)
|
One year
|
Death
Aikaikkuna: One year
|
Overall mortality
|
One year
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- van Griensven J, Edwards T, Baize S; Ebola-Tx Consortium. Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. N Engl J Med. 2016 Dec 8;375(23):2307-2309. doi: 10.1056/NEJMc1609116. Epub 2016 Nov 14. No abstract available.
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
- Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6. doi: 10.1007/s10096-004-1271-9.
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.
- Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]. 2017. Available from: https://www.meddra.org/
- Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004 Jul;10(7):676-8. doi: 10.1111/j.1469-0691.2004.00956.x.
- Francis F, Hall M, Surg, Gaines A. Early use of convalescent serum in influenza. Mil Surg. 1920;47:177-9.
- rice H, Genereux M, Sinclair C. Hyperimmune Immunoglobulin G. In: Production of Plasma Proteins for Therapeutic Use [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2012.
- Vargas M, Segura A, Wu YW, Herrera M, Chou ML, Villalta M, Leon G, Burnouf T. Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity. Vox Sang. 2015 Feb;108(2):169-77. doi: 10.1111/vox.12209. Epub 2014 Dec 3.
- Redden WR. Treatment of Influenza-Pneumonia by Use of Convalescent Human Serum. Bost Med Surg J. 1919 Dec 11;181(24):688-91.
- Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003 Jun;9(3):199-201.
- Zingher A, Mortimer P. Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180-1187. Rev Med Virol. 2005 Nov-Dec;15(6):407-18; discussion 418-21. doi: 10.1002/rmv.480. No abstract available.
- Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks Interim Guidance for National Health Authorities and Blood Transfusion Services Use of Convale. 2014.
- FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency | FDA [Internet]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Odotettu)
Ensisijainen valmistuminen (Odotettu)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Coronaviridae-infektiot
- Nidovirales-infektiot
- RNA-virusinfektiot
- Virussairaudet
- Infektiot
- Hengitysteiden infektiot
- Hengityselinten sairaudet
- Keuhkokuume, virus
- Keuhkokuume
- Keuhkosairaudet
- COVID-19
- Koronavirusinfektiot
- Huumeiden fysiologiset vaikutukset
- Immunologiset tekijät
- Vasta-aineet
- Immunoglobuliinit
- Immunoglobuliinit, suonensisäinen
Muut tutkimustunnusnumerot
- LFCOLCOVID-19-001
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Koronavirustauti 2019 (COVID-19)
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of Excellence; Clinical Trials in Organ Transplantation...ValmisVaikea akuutti hengitystieoireyhtymä Coronavirus 2 (SARS-CoV-2) | Koronavirustauti 2019 (COVID-19) | Lasten monisysteeminen tulehdussyndrooma (MIS-C)Yhdysvallat
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... ja muut yhteistyökumppanitValmisKoronavirustauti 2019 | SARS-CoV-2-infektio | Covid-19-pandemia | COVID-19-virusinfektio | Koronavirustauti-19 | COVID-19 virustauti | 2019 Uusi koronavirustauti | 2019 Uusi koronavirusinfektio | 2019-nCoV-tautiYhdysvallat
-
Leidos Life SciencesUnited States Department of DefenseAktiivinen, ei rekrytointiCOVID-19 | Covid19 | Koronavirustauti 2019 | SARS-CoV-2-infektio | SARS-CoV-2 akuutti hengityselinsairaus | Covid-19-pandemia | COVID-19-virusinfektio | COVID-19 virustauti | 2019 Uusi koronavirustauti | 2019 Uusi koronavirusinfektio | 2019-nCoV-tauti | 2019-nCoV-infektioYhdysvallat
-
Leidos Life SciencesUnited States Department of DefensePeruutettuCOVID-19 | Covid19 | Koronavirustauti 2019 | SARS-CoV-2-infektio | SARS-CoV-2 akuutti hengityselinsairaus | Covid-19-pandemia | COVID-19-virusinfektio | COVID-19 virustauti | 2019 Uusi koronavirustauti | 2019 Uusi koronavirusinfektio | 2019-nCoV-tauti | 2019-nCoV-infektio
-
Leidos Life SciencesUnited States Department of DefenseLopetettuCOVID-19 | Covid19 | Koronavirustauti 2019 | SARS-CoV2-infektio | SARS-CoV-2 akuutti hengityselinsairaus | Covid-19-pandemia | COVID-19-virusinfektio | COVID-19 virustauti | 2019 Uusi koronavirustauti | 2019 Uusi koronavirusinfektio | 2019-nCoV-tauti | 2019-nCoV-infektioYhdysvallat
-
National Institute of Allergy and Infectious Diseases...PPD; University of Washington; Vanderbilt University Medical Center; Implicit...LopetettuVaikea akuutti hengitystieoireyhtymä Coronavirus 2 (SARS-CoV-2) | Koronavirustauti 2019 (COVID-19)Yhdysvallat
-
PfizerPeruutettuVaikea akuutti hengitystieoireyhtymä Coronavirus 2 (SARS-CoV-2) | Koronavirustauti 2019 (COVID-19) | Immuunipuutteinen | Sairaalahoito | Lapsi, sairaalahoidossaYhdysvallat, Bulgaria
-
Akesobio Australia Pty LtdValmisKoronavirustauti 2019 (COVID-19)Uusi Seelanti
-
Janssen Vaccines & Prevention B.V.ValmisKoronavirustaudin 2019 (COVID-19) ehkäisyEtelä-Afrikka, Brasilia, Argentiina, Meksiko, Intia
-
CSL BehringValmisKoronavirustauti 2019 (COVID-19)Yhdysvallat
Kliiniset tutkimukset COVID-19 convalescent plasma
-
Gailen D. Marshall Jr., MD PhDUniversity of Mississippi Medical CenterValmis
-
Priscilla Hsue, MDSan Francisco General Hospital; Blood Systems Research InstituteValmisCOVID-19 | SARS-CoV-2Yhdysvallat
-
University of North Carolina, Chapel HillValmis
-
Institute of Hematology & Blood Diseases HospitalRekrytointiCOVID-19 | Hematopoieettisten kantasolujen siirtoKiina
-
Cristina Avendaño SoláInstituto de Salud Carlos IIIValmis
-
Azienda Ospedaliera Città della Salute e della...Valmis
-
VA Office of Research and DevelopmentLopetettu
-
AstraZenecaValmisCOVID-19Yhdistynyt kuningaskunta
-
Melike CengizValmis
-
Hasanuddin UniversityChulalongkorn UniversityValmis